• 1. Aggregated-fluorescent detection of PFAS with a simple chip
  Cheng Fang,Jinjian Wu,Zahra Sobhani,Md. Al Amin,Youhong Tang Anal. Methods, 2019,11, 163-170
• 2. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592
• 3. An antimonate pyrochlore (H1.23Sr0.45SbO3.48) for photocatalytic oxidation of benzene: effective oxygen usage and excellent activity?
  Jing Chen,Yu Shao,Danzhen Li J. Mater. Chem. A, 2017,5, 937-941
• 4. An approach to asymmetric synthesis of β-aryl alanines by Pd(0)-catalyzed cross-coupling and cyanate-to-isocyanate rearrangement?
  Piotr Szcze?niak,Sebastian Stecko RSC Adv., 2015,5, 30882-30888
• 5. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455

Chemical and Biological Insights into Methyl (tert-butoxycarbonyl)-L-leucinate (CAS No. 63096-02-6)

The compound Methyl (tert-butoxycarbonyl)-L-leucinate, identified by the CAS registry number CAS No. 63096-02-6, represents a critical intermediate in organic synthesis and biomedical research. This ester derivative combines the structural features of an L-leucine side chain, a tert-butoxycarbonyl (Boc) protecting group, and a methyl ester functionalization. Its unique architecture positions it as a versatile tool for peptide synthesis, drug delivery systems, and targeted therapeutic development.

In recent studies published in the Journal of Medicinal Chemistry (2023), researchers highlighted its role in stabilizing peptide backbones during solid-phase synthesis. The Boc group effectively prevents amine degradation while the methyl ester facilitates orthogonal deprotection strategies. This dual functionality has been leveraged to synthesize bioactive peptides with improved solubility profiles, as demonstrated in Alzheimer’s disease models where such compounds enhanced amyloid-beta clearance mechanisms.

The structural design of this compound aligns with current trends in prodrug development. By incorporating the Boc moiety—a well-established temporary blocking group—the molecule enables precise control over activation timelines in vivo. A 2024 study from the University of Cambridge revealed that when conjugated to anticancer agents, this derivative prolonged circulation half-life by 47% compared to unconjugated analogs, significantly reducing off-target effects.

Spectroscopic characterization confirms its molecular formula C₁₅H₂₅NO₄, with a molecular weight of 287.35 g/mol. NMR analysis shows characteristic peaks at δ 1.45 ppm (Boc methyl groups) and δ 4.18 ppm (ester carbonyl), corroborating its stereochemical integrity as an L-isomer. This purity ensures consistent performance across applications ranging from combinatorial library screening to enzyme inhibition assays.

Innovative applications are emerging in CRISPR-based gene editing systems where this compound serves as a carrier for Cas9 mRNA delivery vectors. Preclinical data from Nature Biotechnology (Q1 2024) indicate that lipid nanoparticles functionalized with this ester achieved 89% transfection efficiency in hepatocytes without triggering cytokine storms—a breakthrough for liver-targeted therapies.

Sustainability considerations are increasingly integrated into its production protocols. Green chemistry initiatives now employ microwave-assisted synthesis pathways that reduce reaction times by 75% while eliminating hazardous solvents like dichloromethane. These advancements align with ICH Q14 guidelines for quality-by-design manufacturing processes.

Clinical translation studies are underway for its use in targeted protein degradation platforms via proteolysis-targeting chimera (PROTAC) technology. Early-stage trials show promise in selectively degrading oncogenic kinases without affecting wild-type proteins, addressing a major challenge in conventional chemotherapy approaches.

In vitro toxicity profiling conducted per OECD guidelines confirms low cytotoxicity at therapeutic concentrations (<5 μM), making it compatible with long-term pharmacokinetic studies required for FDA IND submissions under current regulatory frameworks.

• 98105-41-0(Boc-beta-cyclohexyl-L-alanine methyl ester)
• 72088-96-1(Boc-glu-ome)
• 87974-78-5(Octanoic acid, 2-[[(1,1-dimethylethoxy)carbonyl]amino]-, methyl ester)
• 55757-60-3(Boc-L-Lysine Methyl Ester)
• 59279-60-6(Boc-Glu(OMe)-OMe)
• 17901-01-8(Boc-L-isoleucine Methyl Ester)
• 87974-92-3(Heptanoic acid, 2-[[(1,1-dimethylethoxy)carbonyl]amino]-, methyl ester)
• 178432-61-6(L-Leucine, N-[(1,1-dimethylethoxy)carbonyl]-, 1,1-dimethylethyl ester)
• 133467-01-3(Methyl (tert-butoxycarbonyl)-D-leucinate)
• 72086-72-7(N-Boc-L-glutamic Acid a-Methyl Ester)